The media is obsessed with a rounding error. While pundits scramble to "fact-check" whether Donald Trump’s drug pricing math is "impossible," they are missing the forest for the trees. They are arguing about the receipt while the house is on fire. The "mathematically impossible" narrative isn't just lazy journalism; it’s a fundamental misunderstanding of how the pharmaceutical industrial complex actually operates.
The outrage machine claims that saying prices dropped by 50% or 100% is a statistical fantasy. On paper, in a sterile lab of academic economics, they are right. You can’t have a 100% price drop unless the drug is free. But in the real world—the world of rebates, Pharmacy Benefit Managers (PBMs), and gross-to-net spreads—the math is not just broken; it’s a hallucination.
If you think drug pricing is a simple matter of addition and subtraction, you’ve already lost.
The Myth of the "Sticker Price"
Critics love to point at the Consumer Price Index (CPI) for prescription drugs to prove that prices never actually go down. This is the first "lazy consensus" we need to dismantle. The CPI tracks list prices—the arbitrary number a drug manufacturer puts on a box. Almost nobody actually pays that number.
The gap between the List Price and the Net Price (what the manufacturer actually keeps after paying everyone off) is where the real math happens. This is the "Gross-to-Net" bubble. In 2023, the total value of brand-name drug discounts and rebates reached over $250 billion.
When a politician talks about a "100% drop" or "two ways of calculating," they are clumsily gesturing toward this absurdity. I have sat in boardrooms where a drug's list price went up by 10%, but the net price—the actual revenue—dropped by 15% because the PBM demanded a higher kickback to keep the drug on the "preferred" list.
Is the drug getting more expensive or cheaper? Depending on who you ask, the answer is "yes."
Why Your Math Doesn't Matter to the PBM
We need to talk about the middlemen. Cigna (Express Scripts), CVS Health (Caremark), and UnitedHealth Group (OptumRx) control roughly 80% of the market. These are the Pharmacy Benefit Managers. They don’t want lower list prices. They want high list prices with massive rebates.
Imagine a scenario where a manufacturer wants to sell a life-saving insulin for $50. The PBM says, "No. Make the list price $300, give us a $250 rebate, and we’ll put you on the formulary."
- To the patient: The price feels like $300 (especially if they have a high-deductible plan).
- To the manufacturer: The price is $50.
- To the PBM: The price is a $250 profit engine.
When the media mocks "impossible math," they are defending a system where the "real" price is hidden behind layers of non-disclosure agreements. The "two ways of calculating" isn't a lie; it's a description of a bifurcated reality where the patient is the only one paying the imaginary number.
The Most Favored Nation Trap
The core of the argument usually centers on the "Most Favored Nation" (MFN) policy—the idea that the U.S. should pay the lowest price that any other developed country pays. Critics say this is impossible because it would stifle innovation.
Let’s dismantle that.
The U.S. currently subsidizes the rest of the world’s healthcare. We pay the R&D costs; Germany and France reap the benefits of price caps. The "mathematically impossible" claim regarding MFN suggests that if we pay less, the drugs disappear. This is the "innovation ransom."
It’s a scare tactic. Big Pharma spends more on sales and marketing (S&M) and stock buybacks than it does on R&D. In many years, the ratio isn't even close. If we forced MFN pricing, the "math" that breaks isn't the science; it’s the dividend.
The Fallacy of the "Average" Patient
Every "fact-check" article relies on averages. "On average, drug prices rose by 3% last year."
Averages are the shield of the incompetent. If you are a diabetic whose specific insulin brand was excluded from your insurance because of a PBM dispute, your personal inflation rate is 400%. If you switched to a biosimilar that finally hit the market, your price might have dropped 80%.
When a leader says "prices are down," they are often cherry-picking the wins (like the first wave of biosimilars for Humira). When the media says "prices are up," they are cherry-picking the list price hikes on orphan drugs. Both are technically "correct" and both are functionally useless to the person standing at the pharmacy counter.
Stop Asking if the Math is Right
The question "Is this math possible?" is the wrong question. You are asking for a spreadsheet answer to a systemic corruption problem.
The right question is: Why is the pricing data so opaque that "two ways of calculating" is even a plausible defense?
The system is designed to be un-calculable. If you could see the real numbers—the net-net-net price—there would be a riot. The complexity is not a byproduct of the system; the complexity is the system. It is a feature, not a bug, designed to allow every player in the chain to claim they are losing money while they post record quarterly earnings.
The Counter-Intuitive Truth About "Lowering" Prices
If we actually wanted to lower prices, we wouldn't need a 1,000-page bill or a complicated "Most Favored Nation" index. We would do one thing:
Ban the rebate.
If we mandated that the "net price" must be the "list price," the entire house of cards collapses. The PBMs would have no "spread" to skim. The manufacturers would have to compete on the actual cost.
But no one in Washington—on either side of the aisle—actually wants this. The PBMs are too powerful, and the "impossible math" provides a convenient smokescreen for both politicians to make grand claims and for the media to engage in pedantic "fact-checking" that changes nothing.
The "Innovation Ransom" is a Lie
I’ve watched companies burn $100 million on "line extensions"—slightly changing a molecule to renew a patent (evergreening)—while calling it "pivotal research."
When someone tells you that price controls or aggressive negotiation will kill "cutting-edge" cures, they are defending the right of companies to patent-troll. True innovation—the kind that creates a new class of drugs—is rare and often starts with government-funded basic research at universities. Big Pharma just buys the late-stage results.
The math isn't impossible. The math is just inconvenient for the people who own the calculators.
The Reality Check
The next time you see a headline screaming about "mathematical impossibilities" in healthcare policy, look past the percentages.
- List Price is a hallucination.
- Rebates are a legal bribe.
- "Innovation" is often just a marketing budget in a lab coat.
If a politician says they cut prices by 100%, they are talking about a specific scenario where a generic entered the market and wiped out a monopoly. If a journalist says prices went up, they are looking at a list price that no one actually paid.
The industry thrives in this grey area. They want us arguing about whether a 51% drop is "statistically significant" so we don't notice that the base price was 1000% higher than it should have been in the first place.
The math isn't the problem. The system is the problem. Stop trying to "fact-check" the madness and start demanding a system where the math is simple enough for a fifth-grader to follow. Until then, every number you hear is a marketing data point, not a financial reality.
Throw away the calculator. The only number that matters is the one you pay at the window. Everything else is just theater.
